VAPA10: A Treatment Program for Acute Myelocytic Leukemia

  • R. J. Mayer
  • H. J. Weinstein
  • D. S. Rosenthal
  • F. S. Coral
  • D. G. Nathan
  • E. FreiIII
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 26)


During the past decade, the combination of an anthracycline and continuous infusion cytosine arabinoside chemotherapy has been associated with an increase in the complete response rate of patients under age 60 having acute myelocytic leukemia (AML) from 35%-55% (Carey et al. 1975; Clarkson et al. 1975) to approximately 75% (Evans et al. 1975; Gale 1979; Haghbin et al. 1977; Preisler et al. 1979; Rees and Hayhoe 1978; Yates et al. 1973). This encouraging advance, however, has not led to prolonged periods of remission and indefinite survival as seen in childhood acute lymphocytic leukemia. The median duration of complete remission in most recent studies in AML is in the range of 12-14 months (Armitage and Burns 1976; Evans et al. 1975; Haghbin et al. 1977; Moreno et al. 1977; Peterson and Bloomfield 1977; Preisler et al. 1979; Rees and Hayhoe 1978; Spiers et al. 1977). In early 1976 a therapeutic program (VAPA 10 protocol) was initiated in an attempt to overcome the causes of relapse in patients with AML. It was postulated that the high failure rate in AML patients in complete remission might be the result of inadequate cytoreduction during the maintenance period, the development of drug resistance, the presence of “sanctuaries” into which effective chemotherapy could not penetrate, and the presence of a mutant myeloid progenitor cell which over a period of time would progressively replace or even suppress the growth of the differentiated product of normal hematopoiesis. It was appreciated that if the latter possibility were true, it would be unlikely that intensive chemotherapy would have any longterm beneficial effect in patients with AML and that the only rational therapeutic option would be replacement of these progenitor cells through a maneuver such as bone marrow transplantion. Others are presently testing the utility of marrow transplantation in patients with AML shortly after complete remission is obtained (Blume et al. 1980; Powles et al. 1980; Thomas et al. 1979).


Complete Remission Acute Myeloid Leukaemia Cytosine Arabinoside Remission Induction Complete Responder 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Armitage JD, Burns CP (1976) Maintenance of remission in adult acute nonlymphoblastic leukemia using intermittent courses of cytosine arabinoside (NSC-63878) and 6-thioguanine (NSC-752). Cancer Treat Rep 60:585–589PubMedGoogle Scholar
  2. Blume KG et al. (1980) Bone marrow ablation and allogeneic marrow transplantation in acute leukemia. N Engl J Med 302:1041–1046PubMedCrossRefGoogle Scholar
  3. Bodey GP et al. (1976) Late intensification therapy for acute leukemia in remission: Chemotherapy and immunotherapy. JAMA 235:1021–1025PubMedCrossRefGoogle Scholar
  4. Carey RW et al. (1975) Comparative study of cytosine arabinoside therapy alone and combined with thioguanine, mercaptopurine or daunorubicin in acute myelocytic leukemia. Cancer 36:1560–1566PubMedCrossRefGoogle Scholar
  5. Chard RL et al. (1978) Increased survival in childhood acute nonlymphocytic leukemia after treatment with Prednisone, cytosine arabinoside, 6-thioguanine, cyclophosphamide, and oncovin (PATCO) combination chemotherapy. Med Pediatr Oncol 4:263–273PubMedCrossRefGoogle Scholar
  6. Clarkson BD et al. (1975) Treatment of acute leukemia in adults. Cancer 36:775–795PubMedCrossRefGoogle Scholar
  7. Evans DIK et al. (1975) Treatment of acute myeloid leukemia of childhood with cytosine arabinoside, daunorubicin, prednisone, and mercaptopurine or thioguanine. Cancer 36:1547–1551PubMedCrossRefGoogle Scholar
  8. Gale RPL (1979) Advances in the treatment of acute myeologenous leukemia. N Engl J Med 300:1189–1199PubMedCrossRefGoogle Scholar
  9. Haghbin M et al. (1977) Treatment of acute nonlymphoblastic leukemia in children with a multiple drug protocol. Cancer 49:1417–1421CrossRefGoogle Scholar
  10. Henderson ES (1969) Treatment of acute leukemia. Semin Hemat 6:271–319PubMedGoogle Scholar
  11. Ho DHW, Frei E III (1971) Clinical pharmacology of 1-B-D-arabinosylcytosine. Clin Pharmacol Therap 12:944–954Google Scholar
  12. Moreno H et al. (1977) Cytosine arabinoside and 6-thioguanine in the treatment of childhood acute myeloblastic leukemia. Cancer 40:998–1004PubMedCrossRefGoogle Scholar
  13. Peterson BA, Bloomfield CD (1977) Prolonged maintained remission of adult acute nonlymphocytic leukemia. Lancet 2:158–160PubMedCrossRefGoogle Scholar
  14. Pippard MJ et al. (1979) Infiltration of central nervous system in adult acute myeloid leukaemia. Br Med J 1:227–229PubMedCrossRefGoogle Scholar
  15. Pizzo PA et al. (1976) Acute myelogenous leukemia in children: A preliminary report of combination chemotherapy. J Pediatr 88:125–130PubMedCrossRefGoogle Scholar
  16. Powles RL et al. (1980) The place of bone marrow transplantation in acute myelogenous leukaemia. Lancet 1:1047–1050PubMedCrossRefGoogle Scholar
  17. Preisler HD et al. (1979) Treatment of acute nonlymphocytic leukemia: Use of anthracycline-cytosine arabinoside induction therapy and comparison of two maintenance regimens. Blood 53:455–464PubMedGoogle Scholar
  18. Rees JKH, Hayhoe FGJ (1978) DAT (daunorubicin, cytarabine, 6-thioguanine) in acute myeloid leukaemia. Lancet 1:1360–1361PubMedCrossRefGoogle Scholar
  19. Skipper HE (1978) Reasons for success and failure in treatment of murine leukemias with drugs now employed in treating human leukemias. In: Cancer Chemotherapy, Volume I. University Microfilms International: Southern Research InstituteGoogle Scholar
  20. Spiers ASD et al. (1977) Prolonged remission maintenance in acute myeloid leukaemia. Br J Med 2:544–547CrossRefGoogle Scholar
  21. Thomas ED et al. (1979) Marrow transplantation for acute nonlymphoblastic leukemia in first remission. N Eng J Med 301:597–599CrossRefGoogle Scholar
  22. Van Hoff DD et al. (1976) 5-azacytidene: A new anticancer drug with effectiveness in acute myelogenous leukemia. Ann Int Med 82:237–245Google Scholar
  23. Vaughn WP et al. (1980) Long chemotherapy-free remissions after single-cycle timed sequential chemotherapy for acute myelocytic leukemia. Cancer 45:859–865CrossRefGoogle Scholar
  24. Weinstein H et al. (1978) Pharmacology of cytosine arabinoside (a-C). Proc Am Assoc Cancer Res 19:157Google Scholar
  25. Wolk RW et al. (1974) The incidence of central nervous system leukemia in adults with acute leukemia. Cancer 33:863–869PubMedCrossRefGoogle Scholar
  26. Yates JW et al. (1973) Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep 57:485–487PubMedGoogle Scholar
  27. Zachariah C et al. (1978) Prolonged meningeal leukemia: Occurrence during hematologic remission of acute myeloblastic leukemia. JAMA 239:1423–1424.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1981

Authors and Affiliations

  • R. J. Mayer
  • H. J. Weinstein
  • D. S. Rosenthal
  • F. S. Coral
  • D. G. Nathan
  • E. FreiIII

There are no affiliations available

Personalised recommendations